Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

Prednisone (M.S.D.) in the Treatment of Patients with Rheumatoid Arthritis Preliminary Report


Informa UK Ltd
© 1956 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted
Original Article
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

Prednisone (M.S.D.) in the Treatment of Patients with Rheumatoid Arthritis Preliminary Report


I Grenblek, P : Acta Rheum. Scand., 2, 65-74, 1956. . I From The Physical Therapy Department Kommunehospitalet, Copenhagen, Denmark PREDNISONE (M.S.D.) IN T H E TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS Preliminary report BY P A L L E GRBNBAZK The intensive research during recent years to find new therapeutically useful adrenocortical steroids has given us several very active hormones. These new steroids include, La., two hormones with a predominant effect on the carbohydrate metabolism (Prednisone or Deltacortone and Prednisolone or Deltahydrocortone). The formula of this compound derived from cortisone (Prednisone) is shown below and is delta-1.4prednandiene-17 alpha, 21-diol-3.11.20-trione. P -0 H O PREDNISON These two new compounds have introduced a new era in the treatment of rheumatoid arthritis. In preliminary communications it has been reported that the antirheumatic potency of Prednisone is 3-5 times that 66 PALLE GRBNBAEK of cortisone, that the effect occurs rapidly and the toxicity is small. A t the same time it is found that in therapeutic doses Prednisone - unlike cortisone - does not cause retention of sodium and/or loss of potassium. A special diet and supplementation of potassium are not necessary. On the other hand, carbohydrate metabolism has changed; the
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.